<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58655">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01841034</url>
  </required_header>
  <id_info>
    <org_study_id>11-PP-13</org_study_id>
    <nct_id>NCT01841034</nct_id>
  </id_info>
  <brief_title>Impact of an Antioxidant Alimentary Complement on Sperm Data</brief_title>
  <official_title>Evaluation of a 6 Months Treatment of Conceptio (EA) on Sperm Data in Infertile Men With Oligoasthenozoospermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <authority>France: French Data Protection Authority</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Male infertility is a multifactorial disease process with a number of potential contributive
      causes. Considering the majority of male infertility cases are due to deficient sperm
      production of unknown origin, environmental and nutritional factors must be evaluated. The
      purpose of this study is to evaluate the effects of 6 months  antioxidant dietary complement
      (Conceptio) on sperm parameters (sperm count, motility and DNA fragmentation)  in infertile
      men with oligoasthenozoospermia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Spermatic parameters (numeration and mobility spermatic)</measure>
    <time_frame>At the inclusion and 6 months after the inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The spermatic parameters used within the framework of the spermogramme made in routine in the Laboratory of Biology of the Reproduction will be the numeration and the spermatic mobility from the very beginning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of fragmentation of the DNA</measure>
    <time_frame>At the inclusion and 6 months after the inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>We shall consider the rate of fragmentation of the DNA determined according to the method of the TUNEL. This technique allows to estimate the rate of spermatozoides apoptose. It brings to light the fragmentation of the spermatic DNA in the course of process of cellular death.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Conceptio</arm_group_label>
    <description>Any patient receipt within the framework of the coverage(care) of an infertility in the pole ORG, whatever is the étiologie and the type of treatment proposing and presenting during at least two spermogrammes an oligospermie and\or an asthénospermie. The necessity of realizing 2 spermogrammes different to determine the pathological character of the values of a spermogramme takes into account the personal variability of the results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conceptio EA</intervention_name>
    <description>The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.</description>
    <arm_group_label>Conceptio</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient receipt within the framework of the care of an infertility in the pole ORG,
        whatever is the étiologie and the type of treatment proposing and presenting during at
        least two spermogrammes an oligospermie and\or an asthénospermie.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Number of sperm cells &lt; 15M / mL and\or mobility &lt; 40 %.

          -  Signature of a form of not opposition to the research.

          -  Membership in a social security system.

        Exclusion Criteria:

          -  Number of sperm cells = 100M / mL.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ISNARD Véronique, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice - CECOS- Hôpital de l'Archet - 151 Route de saint-antoine de ginestière 06200 Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ISNARD Véronique, PH</last_name>
    <phone>+3349206403</phone>
    <phone_ext>+33492036424</phone_ext>
    <email>isnard.v@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BENHAMED Mohamed, MD</last_name>
    <phone>+3349206403</phone>
    <email>benhamed.m@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ISNARD Véronique, PH</last_name>
      <phone>+3349206403</phone>
      <email>isnard.v@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>BENHAMED Mohamed, MD</last_name>
      <phone>+3349206403</phone>
      <email>benhamed.m@chu-nice.fr</email>
    </contact_backup>
    <investigator>
      <last_name>ISNARD Véronique, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>April 25, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Male</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
